Current and future therapeutic options for persistent pulmonary hypertension in the newborn

Expert Review of Cardiovascular Therapy

Volumn 8, Issue 6, 2010, Pages 845-862

  Rao, Shripada ^a,b,c   Bartle, David ^a,b   Patole, Sanjay ^a,c  

^a KEM Hospital for Women   (Australia)

^b PRINCESS MARGARET HOSPITAL FOR CHILDREN   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Hypertension; Neonates; Newborn; Persistent; Persistent fetal circulation; Pulmonary; Therapy

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ADENOSINE; AMBRISENTAN; BOSENTAN; BUTAPROST; FASUDIL; ILOPROST; MAGNESIUM SULFATE; MILRINONE; NITRIC OXIDE; PLACEBO; PROSTACYCLIN; SILDENAFIL; SITAXSENTAN; SUPEROXIDE DISMUTASE; UNIPROST; ANTIHYPERTENSIVE AGENT; VASODILATOR AGENT;

CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; EXTRACORPOREAL OXYGENATION; FLUSHING; HEART HEMODYNAMICS; HEART OUTPUT; HIGH FREQUENCY VENTILATION; HUMAN; HYPOTENSION; LOADING DRUG DOSE; LUNG HEMODYNAMICS; LUNG HEMORRHAGE; NEWBORN DISEASE; NEWBORN INTENSIVE CARE; NONHUMAN; PATENT DUCTUS ARTERIOSUS; PERSISTENT PULMONARY HYPERTENSION; PULMONARY HYPERTENSION; RESPIRATORY FAILURE; REVIEW; SIDE EFFECT; TACHYCARDIA; TREATMENT OUTCOME; VASCULAR RESISTANCE; VASOCONSTRICTION; VASODILATATION; ANIMAL; ECONOMICS; INHALATIONAL DRUG ADMINISTRATION; NEWBORN; PATHOPHYSIOLOGY; PERSISTENT FETAL CIRCULATION SYNDROME; PREMATURITY;

ADMINISTRATION, INHALATION; ANIMALS; ANIMALS, NEWBORN; ANTIHYPERTENSIVE AGENTS; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; NITRIC OXIDE; PERSISTENT FETAL CIRCULATION SYNDROME; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 77953603513     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.09.186     Document Type: Review

References (187)

1. Gersony W, Duc G, Sinclair J. 'PFC syndrome' (persistence of the fetal circulation). Circulation 40(Suppl. 3), 87 (1969).
2. Abman SH. Recent advances in the pathogenesis and treatment of persistent pulmonary hypertension of the newborn. Neonatology 91(4), 283-290 (2007).
3. Lipkin PH, Davidson D, Spivak L, Straube R, Rhines J, Chang CT. Neurodevelopmental and medical outcomes of persistent pulmonary hypertension in term newborns treated with nitric oxide. J. Pediatr. 140(3), 306-310 (2002).
4. Ivy DD, Parker TA, Kinsella JP, Abman SH. Endothelin A receptor blockade decreases pulmonary vascular resistance in premature lambs with hyaline membrane disease. Pediatr. Res. 44(2), 175-180 (1998).
5. Muraskas JK, Juretschke LJ, Weiss MG, Bhola M, Besinger RE. Neonatal-perinatal risk factors for the development of persistent pulmonary hypertension of the newborn in preterm newborns. Am. J. Perinatol. 18(2), 87-91 (2001).
6. Kinsella JP, Ivy DD, Abman SH. Inhaled nitric oxide improves gas exchange and lowers pulmonary vascular resistance in severe experimental hyaline membrane disease. Pediatr. Res. 36(3), 402-408 (1994).
7. Konduri GG, Kim UO. Advances in the diagnosis and management of persistent pulmonary hypertension of the newborn. Pediatr. Clin. North Am. 56(3), 579-600 (2009).
8. Jankov RP, McNamara PJ. Inhaled nitric oxide therapy for persistent pulmonary hypertension of the newborn: when is it enough? J. Crit. Care 20(3), 294-295 (2005).
9. Steinhorn RH, Kinsella JP, Pierce C et al. Intravenous sildenafil in the treatment of neonates with persistent pulmonary hypertension. J. Pediatr. 155(6), 841-847.e1 (2009).
10. Farrow KN, Fliman P, Steinhorn RH. The diseases treated with ECMO: focus on PPHN. Semin. Perinatol. 29(1), 8-14 (2005).
11. Steinhorn RH. Nitric oxide and beyond: new insights and therapies for pulmonary hypertension. J. Perinatol. 28(Suppl. 3), S67-S71 (2008).
12. Palmer R, Ferrige A, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327(6122), 524-526 (1987). (Pubitemid 17085822)
13. Steudel W, Hurford W, Zapol W. Inhaled nitric oxide: basic biology and clinical applications. Anesthesiology 91(4), 1090-1121 (1999).
14. Bloch K, Ichinose F, Roberts J Jr, Zapol W. Inhaled NO as a therapeutic agent. Cardiovasc. Res. 75(2), 339-348 (2007).
15. Fagan K, Tyler R, Sato K et al. Relative contributions of endothelial, inducible, and neuronal NOS to tone in the murine pulmonary circulation. Am. J. Physiol. 277(3 Pt 1), L472-L478 (1999).
16. Bin-Nun A, Schreiber M. Role of iNO in the modulation of pulmonary vascular resistance. J. Perinatol. 28(Suppl. 3), S84-S92 (2008).
17. Hare J, Stamler J. NO/redox disequilibrium in the failing heart and cardiovascular system. J. Clin. Invest. 115(3), 509-517 (2005).
18. Shekerdemian L, Ravn H, Penny D. Interaction between inhaled nitric oxide and intravenous sildenafil in a porcine model of meconium aspiration syndrome. Pediatr. Res. 55(3), 413-418 (2004). (Pubitemid 38240818)
19. Finer NN, Barrington KJ. Nitric oxide for respiratory failure in infants born at or near term. Cochrane Database Syst. Rev. 4, CD000399 (2006).
20. Soll RF. Inhaled nitric oxide in the neonate. J. Perinatol. 29(Suppl. 2), S63-S67 (2009).
21. Mugford M, Elbourne D, Field D. Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants. Cochrane Database Syst. Rev. 3, CD001340 (2008).
22. Walther FJ, Benders MJ, Leighton JO. Persistent pulmonary hypertension in premature neonates with severe respiratory distress syndrome. Pediatrics 90(6), 899-904 (1992).
23. Skimming JW, DeMarco VG, Cassin S. The effects of nitric oxide inhalation on the pulmonary circulation of preterm lambs. Pediatr. Res. 37(1), 35-40 (1995).
24. Issa A, Lappalainen U, Kleinman M, Bry K, Hallman M. Inhaled nitric oxide decreases hyperoxia-induced surfactant abnormality in preterm rabbits. Pediatr. Res. 45(2), 247-254 (1999).
25. Kinsella J, Parker T, Galan H, Sheridan B, Halbower A, Abman S. Effects of inhaled nitric oxide on pulmonary edema and lung neutrophil accumulation in severe experimental hyaline membrane disease. Pediatr. Res. 41(4 Pt 1), 457-463 (1997).
26. Cotton R, Sundell H, Zeldin D et al. Inhaled nitric oxide attenuates hyperoxic lung injury in lambs. Pediatr. Res. 59(1), 142-146 (2006).
27. McCurnin D, Pierce R, Chang L et al. Inhaled NO improves early pulmonary function and modifies lung growth and elastin deposition in a baboon model of neonatal chronic lung disease. Am. J. Physiol. Lung Cell Mol. Physiol. 288(3), L450-L459 (2005).
28. Tang J, Markham N, Lin Y et al. Inhaled nitric oxide attenuates pulmonary hypertension and improves lung growth in infant rats after neonatal treatment with a VEGF receptor inhibitor. Am. J. Physiol. Lung Cell Mol. Physiol. 287(2), L344-L351 (2004).
29. Lin Y, Markham N, Balasubramaniam V et al. Inhaled nitric oxide enhances distal lung growth after exposure to hyperoxia in neonatal rats. Pediatr. Res. 58(1), 22-29 (2005).
30. Barrington K, Finer N. Inhaled nitric oxide for respiratory failure in preterm infants. Cochrane Database Syst. Rev. 3, CD000509 (2007).
31. Su P, Chen J. Inhaled nitric oxide in the management of preterm infants with severe respiratory failure. J. Perinatol. 28(2), 112-116 (2008).
32. Mercier J. The effects of nitric oxide for inhalation on the development of chronic lung disease in pre-term neonates. Presented at: 2nd Congress of the European Academy of Paediatrics. Nice, France, 24-28 October 2008.
33. Hibbs A, Walsh M, Martin R et al. One-year respiratory outcomes of preterm infants enrolled in the Nitric Oxide (to Prevent) Chronic Lung Disease trial. J. Pediatr. 153(4), 525-529 (2008).
34. Huddy C, Bennett C, Hardy P et al. The INNOVO multicentre randomised controlled trial: neonatal ventilation with inhaled nitric oxide versus ventilatory support without nitric oxide for severe respiratory failure in preterm infants: follow up at 4-5 years. Arch. Dis. Child Fetal Neonatal Ed. 93(6), F430-F435 (2008).
35. Kinsella J, Cutter G, Walsh W et al. Outcomes of premature neonates enrolled in the Early Inhaled Nitric Oxide for the Prevention of Chronic Lung Disease Trial. Abstract in Pediatric Academic Societies' annual meeting. E-PAS 2155.6 (2009).
36. Mercier JC, Olivier P, Loron G, Fontaine R, Maury L, Baud O. Inhaled nitric oxide to prevent bronchopulmonary dysplasia in preterm neonates. Semin. Fetal Neonatal Med. 14(1), 28-34 (2009).
37. Travadi J, Patole S. Phosphodiesterase inhibitors for persistent pulmonary hypertension of the newborn: a review. Pediatr. Pulmonol. 36(6), 529-535 (2003).
38. Ichinose F, Erana-Garcia J, Hromi J et al. Nebulized sildenafil is a selective pulmonary vasodilator in lambs with acute pulmonary hypertension. Crit. Care Med. 29(5), 1000-1005 (2001).
39. Kleinsasser A, Loeckinger A, Hoermann C et al. Sildenafil modulates hemodynamics and pulmonary gas exchange. Am. J. Respir. Crit. Care Med. 163(2), 339-343 (2001).
40. Shekerdemian L, Ravn H, Penny D. Intravenous sildenafil lowers pulmonary vascular resistance in a model of neonatal pulmonary hypertension. Am. J. Respir. Crit. Care Med. 165(8), 1098-1102 (2002).
41. Galie N, Manes A, Negro L, Palazzini M, Bacchi-Reggiani ML, Branzi A. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur. Heart J. 30(4), 394-403 (2009).
42. Stocker C, Penny D, Brizard C, Cochrane A, Soto R, Shekerdemian L. Intravenous sildenafil and inhaled nitric oxide: a randomised trial in infants after cardiac surgery. Intensive Care Med. 29(11), 1996-2003 (2003).
43. Namachivayam P, Theilen U, Butt W, Cooper S, Penny D, Shekerdemian L. sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children. Am. J. Respir. Crit. Care Med. 174(9), 1042-1047 (2006).
44. Peiravian F, Amirghofran A, Borzouee M, Ajami G, Sabri M, Kolaee S. Oral sildenafil to control pulmonary hypertension after congenital heart surgery. Asian Cardiovasc. Thorac. Ann. 15(2), 113-117 (2007).
45. Shah P, Ohlsson A. sildenafil for pulmonary hypertension in neonates. Cochrane Database Syst. Rev. 3, CD005494 (2007).
46. Baquero H, Soliz A, Neira F, Venegas ME, Sola A. Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: a pilot randomized blinded study. Pediatrics 117(4), 1077-1083 (2006).
47. Herrea J, Castillo R, Concha E, Soliz A. Oral sildenafil treatment as an alternative to inhaled NO therapy for persistent pulmonary hypertension of the newborn. Abstract in Pediatric Academic Societies' annual meeting. E-PAS 3724.3 (2006).
48. Soliz A, Concha E, Romero F. Oral sildenafil treatment as therapy for persistent pulmonary hypertension of the newborn: a multicentre randomized trial. Abstract in Pediatric Academic Societies' annual meeting. E-PAS 5420.12 (2009).
49. Vargas-Origel A, Gomez-Rodriguez G, Aldana-Valenzuela C, Vela-Huerta MM, Alarcon-Santos SB, Amador-Licona N. The use of sildenafil in persistent pulmonary hypertension of the newborn. Am. J. Perinatol. 27(3), 225-230 (2009).
50. Baquero H, Venegas M, Lorena V, Fredy N, Augusto S. Neurological follow-up (12-48 months) to patients treated with oral sildenafil for severe neonatal pulmonary hypertension in NICU where the iON is not available. Abstract in Pediatric Academic Societies' annual meeting. E-PAS 3772.2 (2008).
51. Baquero H, Neira F, Venegas M, Sola A, Soliz A. Outcome at 18 months of age after sildenafil therapy for refractory neonatal hypoxemia. Abstract in Pediatric Academic Societies' annual meeting. E-PAS 2119 (2005).
52. Noori S, Friedlich P, Wong P, Garingo A, Seri I. Cardiovascular effects of sildenafil in neonates and infants with congenital diaphragmatic hernia and pulmonary hypertension. Neonatology 91(2), 92-100 (2007).
53. Benavides II, Domonoske C, Lally K, Khan A. The use of sildenafil in infants with refractory pulmonary hypertension secondary to congenital diaphragmatic hernia - one center's experience. Abstract in: Pediatric Academic Societies' Annual Meeting. E-PAS 447 (2006).
54. Lima V, Roque R, Villegas C, Escalante F, Torres A, Leija L. Sildenafil for persistent pulmonary hypertension of the newborn: report of two cases. PAS 57, 1242 (2005).
55. Cavallaro G, Agazzani E, Andaloro L et al. sildenafil and nitric oxide inhalation in neonatal pulmonary hypertension. Three case reports. Pediatr. Med. Chir. 30(3), 149-155 (2008).
56. Obaid L, Johnson S, Bigam D, Cheung P. Intratracheal administration of sildenafil and surfactant alleviates the pulmonary hypertension in newborn piglets. Resuscitation 69(2), 287-294 (2006).
57. Martell M, Blasina F, Silvera F et al. Intratracheal sildenafil in the newborn with pulmonary hypertension. Pediatrics 119(1), 215-216 (2007).
58. Shipley J, Tolman D, Hastillo A, Hess M. Milrinone: basic and clinical pharmacology and acute and chronic management. Am. J. Med. Sci. 311(6), 286-291 (1996).
59. Deb B, Bradford K, Pearl R. Additive effects of inhaled nitric oxide and intravenous milrinone in experimental pulmonary hypertension. Crit. Care Med. 28(3), 795-799 (2000). (Pubitemid 30174280)
60. Stocker CF, Shekerdemian LS, Norgaard MA et al. Mechanisms of a reduced cardiac output and the effects of milrinone and levosimendan in a model of infant cardiopulmonary bypass. Crit. Care Med. 35(1), 252-259 (2007).
61. Monrad ES, McKay RG, Baim DS et al. Improvement in indexes of diastolic performance in patients with congestive heart failure treated with milrinone. Circulation 70(6), 1030-1037 (1984).
62. Albrecht CA, Giesler GM, Kar B, Hariharan R, Delgado RM 3rd. Intravenous milrinone infusion improves congestive heart failure caused by diastolic dysfunction: a brief case series. Tex. Heart Inst. J. 32(2), 220-223 (2005).
63. Lakshminrusimha S, Porta N, Farrow K et al. Milrinone enhances relaxation to prostacyclin and iloprost in pulmonary arteries isolated from lambs with persistent pulmonary hypertension of the newborn. Pediatr. Crit. Care Med. 10(1), 106-112 (2009).
64. Joynt C, Bigam D, Charrois G, Jewell L, Korbutt G, Cheung P. Dose-response effects of milrinone on hemodynamics of newborn pigs with hypoxia-reoxygenation. Intensive Care Med. 34(7), 1321-1329 (2008).
65. Cai J, Su Z, Shi Z, Zhou Y, Xu Z, Yang Y. Nitric oxide and milrinone: combined effect on pulmonary circulation after Fontan-type procedure: a prospective, randomized study. Ann. Thorac. Surg. 86(3), 882-888 (2008).
66. Khazin V, Kaufman Y, Zabeeda D et al. Milrinone and nitric oxide: combined effect on pulmonary artery pressures after cardiopulmonary bypass in children. J. Cardiothorac. Vasc. Anesth. 18(2), 156-159 (2004).
67. Chang A, Atz A, Wernovsky G, Burke R, Wessel D. Milrinone: systemic and pulmonary hemodynamic effects in neonates after cardiac surgery. Crit. Care Med. 23(11), 1907-1914 (1995).
68. McNamara P, Laique F, Muang-In S, Whyte H. Milrinone improves oxygenation in neonates with severe persistent pulmonary hypertension of the newborn. J. Crit. Care 21(2), 217-222 (2006).
69. Bassler D, Choong K, McNamara P, Kirpalani H. Neonatal persistent pulmonary hypertension treated with milrinone: four case reports. Biol. Neonate 89(1), 1-5 (2006).
70. Matot I, Gozal Y. Pulmonary responses to selective phosphodiesterase-5 and phosphodiesterase-3 inhibitors. Chest 125(2), 644-651 (2004).
71. Zamanian RT, Haddad F, Doyle RL, Weinacker AB. Management strategies for patients with pulmonary hypertension in the intensive care unit. Crit. Care Med. 35(9), 2037-2050 (2007).
72. Paradisis M, Evans N, Kluckow M, Osborn D. Randomized trial of milrinone versus placebo for prevention of low systemic blood flow in very preterm infants. J. Pediatr. 154(2), 189-195 (2009).
73. Lamarche Y, Malo O, Thorin E et al. Inhaled but not intravenous milrinone prevents pulmonary endothelial dysfunction after cardiopulmonary bypass. J. Thorac. Cardiovasc. Surg. 130(1), 83-92 (2005).
74. Hentschel T, Yin N, Riad A et al. Inhalation of the phosphodiesterase-3 inhibitor milrinone attenuates pulmonary hypertension in a rat model of congestive heart failure. Anesthesiology 106(1), 124-131 (2007).
75. Haraldsson SA, Kieler-Jensen N, Ricksten SE. The additive pulmonary vasodilatory effects of inhaled prostacyclin and inhaled milrinone in postcardiac surgical patients with pulmonary hypertension. Anesth. Analg. 93(6), 1439-1445 (2001).
76. Sablotzki A, Starzmann W, Scheubel R, Grond S, Czeslick EG. Selective pulmonary vasodilation with inhaled aerosolized milrinone in heart transplant candidates. Can. J. Anaesth. 52(10), 1076-1082 (2005).
77. Denault AY, Lamarche Y, Couture P et al. Inhaled milrinone: a new alternative in cardiac surgery? Semin. Cardiothorac. Vasc. Anesth. 10(4), 346-360 (2006).
78. Lamarche Y, Perrault LP, Maltais S, Tetreault K, Lambert J, Denault AY. Preliminary experience with inhaled milrinone in cardiac surgery. Eur. J. Cardiothorac. Surg. 31(6), 1081-1087 (2007).
79. Mubarak KK. A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension. Respir. Med. 104(1), 9-21 (2009).
80. Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263(5579), 663-665 (1976).
81. Grant S, Goa K. Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures. Drugs 43(6), 889-924 (1992).
82. Herman A. Clinical use of prostaglandins in perspective. Acta Clin. Belg. 38(2), 75-79 (1983).
83. Philips J 3rd, Lyrene R. Prostaglandins, related compounds, and the perinatal pulmonary circulation. Clin. Perinatol. 11(3), 565-579 (1984). (Pubitemid 14017906)
84. Reyes J. Arachidonic acid metabolites and haemodynamics of the neonate. Pediatr. Nephrol. 7(6), 841-844 (1993).
85. Shimokawa H, Flavahan NA, Lorenz RR, Vanhoutte PM. prostacyclin releases endothelium-derived relaxing factor and potentiates its action in coronary arteries of the pig. Br. J. Pharmacol. 95(4), 1197-1203 (1988).
86. Kerbaul F, Brimioulle S, Rondelet B, Dewachter C, Hubloue I, Naeije R. How prostacyclin improves cardiac output in right heart failure in conjunction with pulmonary hypertension. Am. J. Respir. Crit. Care Med. 175(8), 846-850 (2007).
87. Obata H, Sakai Y, Ohnishi S et al. Single injection of a sustained-release prostacyclin analog improves pulmonary hypertension in rats. Am. J. Respir. Crit. Care Med. 177(2), 195-201 (2008).
88. Paramothayan NS, Lasserson TJ, Wells AU, Walters EH. Prostacyclin for pulmonary hypertension in adults. Cochrane Database Syst. Rev. 2, CD002994 (2005).
89. Lammers AE, Hislop AA, Flynn Y, Haworth SG. Epoprostenol treatment in children with severe pulmonary hypertension. Heart 93(6), 739-743 (2007).
90. Nakayama T, Shimada H, Takatsuki S et al. Efficacy and limitations of continuous intravenous epoprostenol therapy for idiopathic pulmonary arterial hypertension in Japanese children. Circ. J. 71(11), 1785-1790 (2007).
91. Consensus statement on the management of pulmonary hypertension in clinical practice in the UK and Ireland. Heart 94(Suppl. 1), i1-i41 (2008).
92. Lock J, Olley P, Coceani F, Swyer P, Rowe R. Use of prostacyclin in persistent fetal circulation. Lancet 1(8130), 1343 (1979).
93. Eronen M, Pohjavuori M, Andersson S, Pesonen E, Raivio KO. Prostacyclin treatment for persistent pulmonary hypertension of the newborn. Pediatr. Cardiol. 18(1), 3-7 (1997).
94. Golzand E, Bar-Oz B, Arad I. Intravenous prostacyclin in the treatment of persistent pulmonary hypertension of the newborn refractory to inhaled nitric oxide. Isr. Med. Assoc. J. 7(6), 408-409 (2005).
95. Santak B, Schreiber M, Kuen P, Lang D, Radermacher P. Prostacyclin aerosol in an infant with pulmonary hypertension. Eur. J. Pediatr. 154(3), 233-235 (1995).
96. Kaapa P, Koivisto M, Ylikorkala O, Kouvalainen K. Prostacyclin in the treatment of neonatal pulmonary hypertension. J. Pediatr. 107(6), 951-953 (1985).
97. Drummond W, Williams B, Blanchard W. Myocardial infarction after prostacyclin (PGI2) treatment of neonatal pulmonary hypertension (PH). Pediatr. Res. 16, 99A (1982).
98. Parker TA, Ivy DD, Kinsella JP et al. Combined therapy with inhaled nitric oxide and intravenous prostacyclin in an infant with alveolar-capillary dysplasia. Am. J. Respir. Crit. Care Med. 155(2), 743-746 (1997).
99. Hougland KT, Null D, Ward RM. Epoprostenol use in PPHN. EPAS 1239 (2005).
100. Mangones T. Intravenous prostacyclin improves oxygenation in PPHN refractory to iNO. Abstract in: Pediatric Academic Societies' Annual Meeting. E-PAS 3360 (2005).
101. Betremieux P, Rolland A, Prioul V, Beuchee A, Pladys P. Systemic hemodynamic effects of the association of inhaled nitric oxide and intravenous prostacyclin for persistent pulmonary hypertension of the newborn. Abstract in: Pediatric Academic Societies' Annual Meeting. E-PAS 2540 (2005).
102. Kelly LK, Porta NF, Goodman DM, Carroll CL, Steinhorn RH. Inhaled prostacyclin for term infants with persistent pulmonary hypertension refractory to inhaled nitric oxide. J. Pediatr. 141(6), 830-832 (2002).
103. Max M, Rossaint R. Inhaled prostacyclin in the treatment of pulmonary hypertension. Eur. J. Pediatr. 158(Suppl. 1), S23-S26 (1999).
104. Rex S, Missant C, Claus P, Buhre W, Wouters PF. Effects of inhaled iloprost on right ventricular contractility, right ventriculo-vascular coupling and ventricular interdependence: a randomized placebo-controlled trial in an experimental model of acute pulmonary hypertension. Crit. Care 12(5), R113 (2008).
105. Noponen T, Nordh A, Berg A et al. Circulatory effects of inhaled iloprost in the newborn preterm lamb. Pediatr. Res. 66(4), 416-422 (2009).
106. Welte M, Zwissler B, Habazettl H, Messmer K. PGI2 aerosol versus nitric oxide for selective pulmonary vasodilation in hypoxic pulmonary vasoconstriction. Eur. Surg. Res. 25(5), 329-340 (1993).
107. Ewert R, Schaper C, Halank M, Glaser S, Opitz CF. Inhalative iloprost - pharmacology and clinical application. Expert Opin. Pharmacother. 10(13), 2195-2207 (2009).
108. Tissot C, Beghetti M. Review of inhaled iloprost for the control of pulmonary artery hypertension in children. Vasc. Health Risk Manag. 5(1), 325-331 (2009).
109. Eifinger F, Sreeram N, Mehler K, Huenseler C, Kribs A, Roth B. Aerosolized iloprost in the treatment of pulmonary hypertension in extremely preterm infants: a pilot study. Klin. Padiatr. 220(2), 66-69 (2008).
110. Olmsted K, Oluola O, Parthiban A, Raghuveer T. Can inhaled prostacyclin stimulate surfactant in ELBW infants? J. Perinatol. 27(11), 724-726 (2007).
111. De Luca D, Zecca E, Piastra M, Romagnoli C. Iloprost as 'rescue' therapy for pulmonary hypertension of the neonate. Paediatr. Anaesth. 17(4), 394-395 (2007).
112. Ehlen M, Wiebe B. Iloprost in persistent pulmonary hypertension of the newborn. Cardiol. Young 13(4), 361-363 (2003).
113. Bindl L, Fahnenstich H, Peukert U. Aerosolised prostacyclin for pulmonary hypertension in neonates. Arch. Dis. Child Fetal Neonatal Ed. 71(3), F214-F216 (1994).
114. De Jaegere A, van den Anker J. Endotracheal instillation of prostacyclin in preterm infants with persistent pulmonary hypertension. Eur. Respir. J. 12(4), 932-934 (1998).
115. Soditt V, Aring C, Groneck P. Improvement of oxygenation induced by aerosolized prostacyclin in a preterm infant with persistent pulmonary hypertension of the newborn. Intensive Care Med. 23(12), 1275-1278 (1997).
116. Chotigeat U, Jaratwashirakul S. Inhaled iloprost for severe persistent pulmonary hypertension of the newborn. J. Med. Assoc. Thai. 90(1), 167-170 (2007).
117. Hsiao R OS. Inhaled aerosolized prostacyclin (IAP) for premature infants with PPHN. Abstract in Pediatric Academic Societies' annual meeting. E-PAS 3085 (2004).
118. Coceani F, Olley PM. The response of the ductus arteriosus to prostaglandins. Can. J. Physiol. Pharmacol. 51(3), 220-225 (1973).
119. Smith GC. The pharmacology of the ductus arteriosus. Pharmacol. Rev. 50(1), 35-58 (1998).
120. Naka Y, Roy D, Liao H et al. cAMP-mediated vascular protection in an orthotopic rat lung transplant model. Insights into the mechanism of action of prostaglandin E1 to improve lung preservation. Circ. Res. 79(4), 773-783 (1996).
121. Haworth SG, Hislop AA. Treatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Service for Children 2001-2006. Heart 95(4), 312-317 (2009).
122. McLaughlin VV, Archer SL, Badesch DB et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 119(16), 2250-2294 (2009).
123. Hammerman C, Aramburo M, Choi J. Prostaglandin E1 selectively reduces group B b-hemolytic streptococci-induced pulmonary hypertension in newborn piglets. Am. J. Dis. Child. 143(3), 343-347 (1989).
124. Filan P, McDougall P, Shekerdemian L. Combination pharmacotherapy for severe neonatal pulmonary hypertension. J. Paediatr. Child Health 42(4), 219-220 (2006).
125. Inamura N, Kubota A, Nakajima T et al. A proposal of new therapeutic strategy for antenatally diagnosed congenital diaphragmatic hernia. J. Pediatr. Surg. 40(8), 1315-1319 (2005).
126. Shiyanagi S, Okazaki T, Shoji H et al. Management of pulmonary hypertension in congenital diaphragmatic hernia: nitric oxide with prostaglandin-E1 versus nitric oxide alone. Pediatr. Surg. Int. 24(10), 1101-1104 (2008).
127. Iseri L, French J. Magnesium: nature's physiologic calcium blocker. Am. Heart J. 108(1), 188-193 (1984).
128. Doyle LW, Crowther CA, Middleton P, Marret S. Antenatal magnesium sulfate and neurologic outcome in preterm infants: a systematic review. Obstet. Gynecol. 113(6), 1327-1333 (2009).
129. Bhat MA, Charoo BA, Bhat JI, Ahmad SM, Ali SW, Mufti MU. Magnesium sulfate in severe perinatal asphyxia: a randomized, placebo-controlled trial. Pediatrics 123(5), e764-e769 (2009).
130. Ali A, Goldberg RN, Suguihara C et al. Effects of ATP-magnesium chloride on the cardiopulmonary manifestations of group B streptococcal sepsis in the piglet. Pediatr. Res. 39(4 Pt 1), 609-615 (1996). (Pubitemid 26128147)
131. Anderson ME, Burnette TM, Geiser DR, Janjindamai W. Magnesium attenuates pulmonary hypertension due to hypoxia and group B streptococci. J. Appl. Physiol. 77(2), 751-756 (1994).
132. Barrington KJ, Ryan CA, Finer NN. Effects of magnesium sulfate in a newborn piglet meconium aspiration model. J. Perinatol. 20(6), 373-378 (2000).
133. Beghetti M, Spahr-Schopfer I, Mensi N, Morel D, Rimensberger P. Effects of inhaled nitric oxide and intravenous magnesium sulphate, alone and in combination, in a porcine model of hypoxic pulmonary hypertension. Med. Sci. Monit. 9(6), BR193-BR198 (2003).
134. Ryan C, Finer N, Barrington K. Effects of magnesium sulphate and nitric oxide in pulmonary hypertension induced by hypoxia in newborn piglets. Arch. Dis. Child Fetal Neonatal Ed. 71(3), F151-F155 (1994).
135. Tolsa JF, Cotting J, Sekarski N, Payot M, Micheli JL, Calame A. Magnesium sulphate as an alternative and safe treatment for severe persistent pulmonary hypertension of the newborn. Arch. Dis. Child. Fetal Neonatal Ed. 72(3), F184-F187 (1995).
136. Wu TJ, Teng RJ, Tsou KI. Persistent pulmonary hypertension of the newborn treated with magnesium sulfate in premature neonates. Pediatrics 96(3 Pt 1), 472-474 (1995).
137. Daffa SH, Milaat WA. Role of magnesium sulphate in treatment of severe persistent pulmonary hypertension of the neoborn. Saudi Med. J. 23(10), 1266-1269 (2002).
138. Chandran S, Haqueb ME, Wickramasinghe HT, Wint Z. Use of magnesium sulphate in severe persistent pulmonary hypertension of the newborn. J. Trop. Pediatr. 50(4), 219-223 (2004).
139. Raimondi F, Migliaro F, Capasso L et al. Intravenous magnesium sulphate vs. inhaled nitric oxide for moderate, persistent pulmonary hypertension of the newborn. A multicentre, retrospective study. J. Trop. Pediatr. 54(3), 196-199 (2008).
140. Ho J, Rasa G. Magnesium sulfate for persistent pulmonary hypertension of the newborn. Cochrane Database Syst. Rev. 3, CD005588 (2007).
141. Abu-Osba Y, Galal O, Manasra K, Rejjal A. Treatment of severe persistent pulmonary hypertension of the newborn with magnesium sulphate. Arch. Dis. Child. 67(1 Spec. No.), 31-35 (1992).
142. Dakshinamurti S. Pathophysiologic mechanisms of persistent pulmonary hypertension of the newborn. Pediatr. Pulmonol. 39(6), 492-503 (2005).
143. Yanagisawa M, Kurihara H, Kimura S et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332(6163), 411-415 (1988).
144. Abman SH. Role of endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. Annu. Rev. Med. 60, 13-23 (2009).
145. Giaid A, Yanagisawa M, Langleben D et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N. Engl J. Med. 328(24), 1732-1739 (1993). (Pubitemid 23170122)
146. Davenport A, Maguire J. Endothelin. Handb. Exp. Pharmacol. (176 Pt 1), 295-329 (2006).
147. Galie N, Rubin L, Hoeper M et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 371(9630), 2093-2100 (2008).
148. Rubin L, Badesch D, Barst R et al. Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. 346(12), 896-903 (2002). (Pubitemid 34984638)
149. Liu C, Chen J, Gao Y, Deng B, Liu K. Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database Syst. Rev. 3, CD004434 (2009).
150. Beghetti M. Bosentan in pediatric patients with pulmonary arterial hypertension. Curr. Vasc. Pharmacol. 7(2), 225-233 (2009).
151. Opitz CF, Ewert R, Kirch W, Pittrow D. Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter? Eur. Heart J. 29(16), 1936-1948 (2008).
152. Rosenberg A, Kennaugh J, Koppenhafer S, Loomis M, Chatfield B, Abman S. Elevated immunoreactive endothelin-1 levels in newborn infants with persistent pulmonary hypertension. J. Pediatr. 123(1), 109-114 (1993).
153. Peng J, Ladino J, Hehre D, Bancalari E, Suguihara E. Effects of a selective endothelin A (ETA) receptor antagonist on GBS-induced pulmonary hypertension in newborn piglets. Abstract in Pediatric Academic Societies' annual meeting. E-PAS 2443 (2003).
154. Kuo C. Endothelin-A receptor antagonist prevents neonatal pulmonary hypertension in meconium aspiration in piglets. J. Formos. Med. Assoc. 100(6), 420-423 (2001).
155. Nakwan N, Choksuchat D, Saksawad R, Thammachote P. Successful treatment of persistent pulmonary hypertension of the newborn with bosentan. Acta Paediatr. 98(10), 1683-1685 (2009).
156. Goissen C, Ghyselen L, Tourneux P et al. Persistent pulmonary hypertension of the newborn with transposition of the great arteries: successful treatment with bosentan. Eur. J. Pediatr. 167(4), 437-440 (2008).
157. Konduri G, Theodorou A. Nitro-l-arginine attenuates pulmonary vasodilation caused by adenosine in fetal lambs. Pediatr. Res. 31, 62 (1992).
158. Cooper D, Lewis G, Lieberman G, Webb H, Westwick J. ADP metabolism in vascular tissue, a possible thrombo-regulatory mechanism. Thromb. Res. 14(6), 901-914 (1979).
159. Konduri G, Woodard L, Mukhopadhyay A, Deshmukh D. Adenosine is a pulmonary vasodilator in newborn lambs. Am. Rev. Respir. Dis. 146(3), 670-676 (1992).
160. Konduri G, Garcia D, Kazzi N, Shankaran S. Adenosine infusion improves oxygenation in term infants with respiratory failure. Pediatrics 97(3), 295-300 (1996). (Pubitemid 26076252)
161. Konduri G, Gervasio C, Theodorou A. Role of adenosine triphosphate and adenosine in oxygen-induced pulmonary vasodilation in fetal lambs. Pediatr. Res. 33(5), 533-539 (1993).
162. Patole S, Lee J, Whitehall J. Adenosine infusion in the management of a micropremi neonate with pulmonary hypertension. Indian Pediatr. 36(3), 307-310 (1999).
163. Patole S, Lee J, Buettner P, Whitehall J. Improved oxygenation following adenosine infusion in persistent pulmonary hypertension of the newborn. Biol. Neonate 74(5), 345-350 (1998).
164. Ng C, Franklin O, Vaidya M, Pierce C, Petros A. Adenosine infusion for the management of persistent pulmonary hypertension of the newborn. Pediatr. Crit. Care Med. 5(1), 10-13 (2004).
165. Mark AE. Hypoxic pulmonary vasoconstriction. Essays Biochem. 43, 61-76 (2007).
166. Shimoda LA, Sham JS, Sylvester JT. Altered pulmonary vasoreactivity in the chronically hypoxic lung. Physiol. Res. 49(5), 549-560 (2000).
167. Lakshminrusimha S, Russell JA, Steinhorn RH et al. Pulmonary hemodynamics in neonatal lambs resuscitated with 21%, 50%, and 100% oxygen. Pediatr. Res. 62(3), 313-318 (2007).
168. Maltepe E, Saugstad OD. Oxygen in health and disease: regulation of oxygen homeostasis - clinical implications. Pediatr. Res. 65(3), 261-268 (2009).
169. Sanderud J, Bjoro K, Saugstad OD. Oxygen radicals stimulate thromboxane and prostacyclin synthesis and induce vasoconstriction in pig lungs. Scand. J. Clin. Lab Invest. 53(5), 447-455 (1993).
170. Lakshminrusimha S, Russell JA, Wedgwood S et al. Superoxide dismutase improves oxygenation and reduces oxidation in neonatal pulmonary hypertension. Am. J. Respir. Crit. Care Med. 174(12), 1370-1377 (2006).
171. Farrow KN, Lakshminrusimha S, Reda WJ et al. Superoxide dismutase restores eNOS expression and function in resistance pulmonary arteries from neonatal lambs with persistent pulmonary hypertension. Am. J. Physiol. Lung Cell Mol. Physiol. 295(6), L979-L987 (2008).
172. Farrow KN, Groh BS, Schumacker PT et al. Hyperoxia increases phosphodiesterase 5 expression and activity in ovine fetal pulmonary artery smooth muscle cells. Circ. Res. 102(2), 226-233 (2008).
173. Lakshminrusimha S, Swartz DD, Gugino SF et al. Oxygen concentration and pulmonary hemodynamics in newborn lambs with pulmonary hypertension. Pediatr. Res. 66(5), 539-544 (2009). Study documenting the effects of varying concentrations of oxygen on pulmonary hemodynamics in pulmonary hypertension.
174. Brennan LA, Steinhorn RH, Wedgwood S et al. Increased superoxide generation is associated with pulmonary hypertension in fetal lambs: a role for NADPH oxidase. Circ. Res. 92(6), 683-691 (2003).
175. Teng RJ, Eis A, Bakhutashvili I, Arul N, Konduri GG. Increased superoxide production contributes to the impaired angiogenesis of fetal pulmonary arteries with in utero pulmonary hypertension. Am. J. Physiol. Lung Cell Mol. Physiol. 297(1), L184-L195 (2009).
176. Firth AL, Yuan JX. Bringing down the ROS: a new therapeutic approach for PPHN. Am. J. Physiol. Lung Cell Mol. Physiol. 295(6), L976-L978 (2008).
177. Gong MC, Fujihara H, Walker LA, Somlyo AV, Somlyo AP. Down-regulation of G-protein-mediated Ca2+ sensitization in smooth muscle. Mol. Biol. Cell 8(2), 279-286 (1997). (Pubitemid 27097943)
178. Gong MC, Fujihara H, Somlyo AV, Somlyo AP. Translocation of rhoA associated with Ca2+ sensitization of smooth muscle. J. Biol. Chem. 272(16), 10704-10709 (1997).
179. Kimura K, Ito M, Amano M et al. Regulation of myosin phosphatase by rho and rho-associated kinase (rho-kinase). Science 273(5272), 245-248 (1996).
180. Nossaman BD, Kadowitz PJ. The role of the RhoA/rho-kinase pathway in pulmonary hypertension. Curr. Drug Discov. Technol. 6(1), 59-71 (2009).
181. Shimokawa H, Takeshita A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler. Thromb. Vasc. Biol. 25(9), 1767-1775 (2005).
182. Barman SA, Zhu S, White RE. RhoA/ Rho-kinase signaling: a therapeutic target in pulmonary hypertension. Vasc. Health Risk Manag. 5, 663-671 (2009).
183. Parker TA, Roe G, Grover TR, Abman SH. Rho kinase activation maintains high pulmonary vascular resistance in the ovine fetal lung. Am. J. Physiol. Lung Cell Mol. Physiol. 291(5), L976-L982 (2006).
184. Nagaoka T, Fagan KA, Gebb SA et al. Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension. Am. J. Respir. Crit. Care Med. 171(5), 494-499 (2005).
185. Katz SL, Adatia I, Louca E et al. Nebulized therapies for childhood pulmonary hypertension: an in vitro model. Pediatr. Pulmonol. 41(7), 666-673 (2006).
186. Chen YF, Jowett S, Barton P et al. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation. Health Technol. Assess. 13(49), 1-320 (2009).
187. Nadeau S, Baribeau J, Janvier A, Perreault T. Changes in expression of vascular endothelial growth factor and its receptors in neonatal hypoxia-induced pulmonary hypertension. Pediatr. Res. 58(2), 199-205 (2005)